Next Article in Journal
Emerging Roles of Estrogen-Related Receptors in the Brain: Potential Interactions with Estrogen Signaling
Previous Article in Journal
Applications of CRISPR/Cas System to Bacterial Metabolic Engineering
Case Report

Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation

1
Department of Neurology, University of Cologne, 50937 Cologne, Germany
2
Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Juelich, 52425 Juelich, Germany
3
Institute of Neuropathology, University of Cologne, 50937 Cologne, Germany
4
Center of Integrated Oncology (CIO), Universities of Bonn and Cologne, 50937 Cologne, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2018, 19(4), 1090; https://doi.org/10.3390/ijms19041090
Received: 19 March 2018 / Revised: 2 April 2018 / Accepted: 5 April 2018 / Published: 5 April 2018
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Novel therapeutic targets in malignant glioma patients are urgently needed. Point mutations of the v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene occur predominantly in melanoma patients, but may also occur in gliomas. Thus, this is a target of great interest for this group of patients. In a nine-year-old male patient, an anaplastic astrocytoma in the left temporoparietal region was diagnosed histologically. After first- and second-line treatment, a malignant progression to a secondary glioblastoma was observed ten years after the initial diagnosis. Within the following seven years, all other conventional treatment options were exhausted. At this time point, recurrent tumor histology revealed an epithelioid glioblastoma, without a mutation in the isocitrate dehydrogenase gene (IDH wild-type). In order to identify a potential target for an experimental salvage therapy, mutational tumor analysis showed a BRAF V600E mutation. Consecutively, dabrafenib treatment was initiated. The patient remained clinically stable, and follow-up magnetic resonance images (MRI) were consistent with “Stable Disease” according to the Response Assessment in Neuro-Oncology Working Group (RANO) criteria for the following ten months until tumor progression was detected. The patient died 16 months after dabrafenib treatment initiation. Particularly in younger glioma patients as well as in patients with an epithelioid glioblastoma, screening for a V600E BRAF mutation is promising since, in these cases, targeted therapy with BRAF inhibitors seems to be a useful salvage treatment option. View Full-Text
Keywords: targeted therapy; BRAF inhibitors; epithelioid glioblastoma; xanthoastrocytoma targeted therapy; BRAF inhibitors; epithelioid glioblastoma; xanthoastrocytoma
Show Figures

Figure 1

MDPI and ACS Style

Ceccon, G.; Werner, J.-M.; Dunkl, V.; Tscherpel, C.; Stoffels, G.; Brunn, A.; Deckert, M.; Fink, G.R.; Galldiks, N. Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. Int. J. Mol. Sci. 2018, 19, 1090. https://doi.org/10.3390/ijms19041090

AMA Style

Ceccon G, Werner J-M, Dunkl V, Tscherpel C, Stoffels G, Brunn A, Deckert M, Fink GR, Galldiks N. Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. International Journal of Molecular Sciences. 2018; 19(4):1090. https://doi.org/10.3390/ijms19041090

Chicago/Turabian Style

Ceccon, Garry; Werner, Jan-Michael; Dunkl, Veronika; Tscherpel, Caroline; Stoffels, Gabriele; Brunn, Anna; Deckert, Martina; Fink, Gereon R.; Galldiks, Norbert. 2018. "Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation" Int. J. Mol. Sci. 19, no. 4: 1090. https://doi.org/10.3390/ijms19041090

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop